CRISPR/$CRSP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- Ticker
- $CRSP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 393
- Headquarters
- Zug, Switzerland
- Website
- www.crisprtx.com
CRISPR Metrics
BasicAdvanced
$4.8B
-
-$4.76
1.76
-
Price and volume
Market cap
$4.8B
Beta
1.76
52-week high
$64.74
52-week low
$44.12
Average daily volume
1.5M
Financial strength
Current ratio
17.847
Quick ratio
17.791
Long term debt to equity
0.438
Total debt to equity
0.449
Profitability
EBITDA (TTM)
-513.174
Gross margin (TTM)
-3,448.33%
Net profit margin (TTM)
-3,368.72%
Operating margin (TTM)
-3,971.53%
Effective tax rate (TTM)
-0.68%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-14.20%
Return on equity (TTM)
-26.09%
Valuation
Price to revenue (TTM)
353.924
Price to book
2.77
Price to tangible book (TTM)
2.77
Price to free cash flow (TTM)
-12.68
Free cash flow yield (TTM)
-7.89%
Free cash flow per share (TTM)
-3.942
Growth
Revenue change (TTM)
-64.80%
Earnings per share change (TTM)
-12.57%
3-year revenue growth (CAGR)
-57.14%
10-year revenue growth (CAGR)
24.32%
3-year earnings per share growth (CAGR)
-3.51%
10-year earnings per share growth (CAGR)
-5.09%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Analyst projections of the future price of CRISPR stock.
Bulls say / Bears say
CASGEVY’s commercial launch is accelerating: Q2 2026 revenue reached $76 million, up 151% year on year, and US approval for children aged two and over made about 5,500 more patients eligible. This gives CRISPR a growing commercial base beyond its research pipeline. (CRISPR Therapeutics)
CTX310 has shown durable ANGPTL3 editing, with lower triglyceride and LDL levels one year after treatment in early clinical data. If further trials confirm the effect, it could extend the company’s gene-editing platform into cardiovascular disease. (GlobeNewswire)
CRISPR had $2.36 billion in cash, cash equivalents and marketable securities at the end of June 2026. That gives it substantial resources to advance its pipeline, including newly started Phase 1 trials for refractory hypertension and alpha-1 antitrypsin deficiency. (CRISPR Therapeutics)
CASGEVY’s treatment process remains slow: the journey from patient initiation to treatment can take six to nine months or longer. That delay makes it harder to turn patient interest quickly into completed treatments and revenue. (MarketBeat)
CRISPR reported a $91.2 million net loss in Q2 2026 despite CASGEVY’s revenue growth. The company therefore still needs its commercial business to scale while it funds research and development. (StockTitan)
CTX310 faces a tough competitive test in severe hypertriglyceridaemia: plozasiran has shown about an 80% median triglyceride reduction in Phase 3 studies, while CTX310 is still in Phase 1b. CRISPR must show that its approach can compete in the target patient group. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRISPR News
AllArticlesVideos
Funds containing CRISPR
AllUSDEURGBP
Fund name | Fund size | $CRSP weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.43% |
iShares Ageing Population£AGES | $953M | 0.43% |
iShares Ageing Population€AGED | $903M | 0.43% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.32% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.32% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.